Incretin and adipose-axis peptides — the most actively studied class in modern peptide research.
Metabolic peptides are the signaling molecules the body already uses to coordinate glucose handling, satiety, and energy expenditure. The current research wave centers on incretin biology — the gut-derived hormones that tune insulin secretion to nutrient intake — and on engineered analogs that extend those short-lived native signals into durable pharmacology. This page is a research reference to the mechanisms involved and the compounds catalogued here; it is not medical or dosing guidance.
Native incretins such as GLP-1 and GIP are released from the gut in response to nutrients and act on pancreatic, gastric, and central targets — but they are degraded within minutes by DPP-4. The defining engineering problem for this class has been resistance to that degradation: amino-acid substitutions, fatty-acid acylation, and albumin-binding moieties all extend half-life from minutes to days, converting a transient meal signal into a once-weekly pharmacological one.
Single-receptor GLP-1 agonism drives glucose-dependent insulin secretion, slowed gastric emptying, and central appetite suppression. Dual GIP/GLP-1 co-agonism layers a complementary insulinotropic and adipose-tissue signal on top of that. Triple agonism adds glucagon-receptor activity, which is associated in research with increased energy expenditure and hepatic lipid handling — the rationale behind the steepest body-composition endpoints reported in recent trials.
A parallel branch of the class works outside the incretin system entirely. Amylin analogs recruit calcitonin and amylin receptors for a distinct satiety signal studied in combination with GLP-1 agonists. Other catalogued compounds act on adipose tissue or cofactor metabolism directly rather than through gut-hormone receptors, which is why this category spans more than the GLP-1 headline names.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
View profileThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
View profileDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
View profileInvestigational once-weekly triple agonist (GIP / GLP-1 / glucagon) — the molecule some in the research community nickname "GLP-3" — with the largest weight reductions reported for any incretin-class agent.
View profileInvestigational glucagon / GLP-1 dual agonist from Boehringer Ingelheim — Phase 3 for obesity and MASH.
View profileA glucagon / GLP-1 dual agonist (oxyntomodulin-based) approved in China for weight management and diabetes — not yet FDA-approved.
View profileLong-acting amylin analog — Novo Nordisk’s answer to GLP-1 from a second satiety pathway, studied alone and as half of CagriSema. Phase 3 monotherapy reported ~11.8% mean weight loss.
View profileNovo Nordisk’s fixed once-weekly combination of cagrilintide (amylin) + semaglutide (GLP-1) — 20.4%–22.7% mean weight loss in Phase 3, filed with the FDA in December 2025.
View profileGHRH analog FDA-approved for HIV-associated lipodystrophy.
View profileThe body’s brake on muscle growth — a TGF-β-family growth factor whose inhibition is the leading strategy to preserve muscle, including during GLP-1 weight loss.
View profileA natural myostatin and activin antagonist — by neutralizing the muscle brake it is one of the most potent pro-muscle factors studied, and a doping and gene-therapy flashpoint.
View profileAn anti-myostatin antibody (Regeneron) now studied in obesity combinations to cut lean-mass loss and deepen fat loss alongside semaglutide.
View profileAn anti-activin-A antibody (Regeneron) — the first drug on the whole activin/myostatin axis to reach FDA approval (as Pasatru, for the rare bone disease FOP), and the activin-A leg of obesity muscle-preservation combinations.
View profileMitochondrially-encoded peptide with reported insulin-sensitizing activity.
View profileSynthetic Lys-Glu-Asp-Trp tetrapeptide studied as a pancreas-tissue bioregulator.
View profileThe lipolytic C-terminal fragment of human growth hormone — the parent peptide that AOD-9604 was engineered from.
View profileC-terminal hGH fragment (177–191) historically investigated for lipolysis.
View profileA fat-targeting proapoptotic peptide that destroys the blood supply of white fat — striking in animals, but discontinued in humans for kidney toxicity.
View profileSmall-molecule NNMT inhibitor (often catalogued alongside peptides).
View profileThe pancreas’s second satiety hormone — co-secreted with insulin from the beta cell; its stabilized analog pramlintide treats diabetes, and the class now drives a new wave of obesity drugs.
View profileThe stabilized amylin analog — three prolines that stop native amylin from aggregating, turning the beta cell’s second satiety hormone into an injectable diabetes drug.
View profileIn this catalog, a metabolic peptide is a peptide or peptide-like compound whose primary studied activity is on glucose handling, satiety, or energy expenditure — most commonly through the incretin receptors (GLP-1, GIP, glucagon) or the amylin system. Entries are reference profiles, not products or treatment recommendations.
A GLP-1 agonist activates a single incretin receptor. Dual agonists (GIP/GLP-1) co-activate two complementary pathways; triple agonists add glucagon-receptor activity associated with increased energy expenditure in research. Each added axis is, broadly, associated with larger body-composition effects in published trials, alongside a distinct research and tolerability profile.
Native incretins are cleared within minutes by the enzyme DPP-4. Substitutions, fatty-acid acylation, and albumin-binding linkers make analogs resistant to that clearance, extending exposure from minutes to days and enabling once-weekly research dosing schedules.
No. AmericanPeptide.com is a computational research and reference platform, not a medical device or clinical decision-support system. Nothing here is medical advice, a dosing protocol, or an offer to sell. Independent expert and regulatory review is required before any experimental use.